Home > Press > Stellar Biotechnologies Provides Quarterly Update/Outlook and Comments on CBS News Cancer Vaccine Story
Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (PINKSHEETS: SBOTF) has been advancing on several fronts over their first quarter as a public company, and expects to achieve new milestones before year end.
Stellar Biotechnologies Provides Quarterly Update/Outlook and Comments on CBS News Cancer Vaccine Story
Port Hueneme, CA | Posted on October 13th, 2010
The Company would like to comment on the recent, featured CBS Evening News report (see video link below) by Dr. Sanjay Gupta on a KLH-based glioblastoma vaccine in development by Celldex Therapeutics about which it has received enquiries.
On October 4th CBS Evening News with Katie Couric featured Dr. Sanjay Gupta in a story about a KLH-based brain cancer vaccine being tested in patients at Duke University for Celldex Therapeutics (*).
John S. Sundsmo, Ph.D., Stellar's VP of Research & Intellectual Property Management, said "Molecular biology is identifying genetic modifications in certain cancer cells that constitute targets for cancer vaccines. Dr. Sanjay Gupta discusses the initial successes observed with glioblastoma multiforme (GBM), normally a rapidly progressing form of brain cancer. The cancer vaccine in the report was produced by Celldex Therapeutics by coupling a cancer-specific protein onto the immune carrier protein KLH. The very early stage results for some patients show signs in MRIs that their tumors may have decreased. While the immune system is highly effective in protecting us against bacteria, cancer cells are extremely difficult to kill and effective killing is mediated by a specialized class of killer T-cells. In this respect, KLH, the hemocyanin protein from the giant keyhole limpet, can be seen as rather unique. KLH stimulates highly effective cell-mediated immunity that results in the production of cancer-killing T-cells. This is offering new hope for patients with previously incurable cancers." Discussions between Celldex and Stellar have been underway.
On September 9th Stellar announced that it had filed for patent protection of inventions related to its Immunogenic (IMG) KLH technology platforms (1)
On September 13th the Company announced a milestone payment from Bayer Innovation (a wholly owned subsidiary of international pharmaceutical company, Bayer AG: (PINKSHEETS: BAYRY) and the achievement of a critical milestone in our Joint Development Agreement (2)
On September 29th Stellar disclosed a CDN $1.05M private placement with a strategic investor and the retirement of 1.66 million shares to the treasury (3)
On September 30th the Company announced receipt of $288,000 from a single biotechnology and immunotherapy products company developing KLH-based therapeutic vaccines for Rheumatoid Arthritis and Lupus for fiscal year ending August 30, 2010 (4)
first Annual General Meeting since public
status of grants that have been applied for by Stellar's California subsidiary
launch date for sales of immunotox products aimed at the pre-clinical market, related to our ongoing research designed to advance Stellar's immune response diagnostic platform
research and regulatory developments related to our new IMG KLH product platform
advancements related to our relationships with Bayer Innovation and several new customers
in and out-licensing and long-term supply agreements, as well as new KLH orders.
(*) (3 minute video: www.cbsnews.com/video/watch/?id=6927121n&tag=related;photovideo
a short article here: www.acsh.org/factsfears/newsID.1920/news_detail.asp)
Statements in these press releases other than purely historical factual information, including statements relating to revenues or profits, or the Company's future plans and objectives, or expected sales, cash flows, and capital expenditures constitute forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks inherent in the technology history. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. These news releases do not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.
About Stellar Biotechnologies
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This ancient evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.
For more information, please click here
Darrell Brookstein, Executive VP, Business Development & Finance
Copyright © Stellar Biotechnologies
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
News and information
Scientists Capture Ultrafast Snapshots of Light-Driven Superconductivity: X-rays reveal how rapidly vanishing 'charge stripes' may be behind laser-induced high-temperature superconductivity April 16th, 2014
'Life Redesigned: The Emergence of Synthetic Biology' Lecture at Brookhaven Lab on Wednesday, April 30: Biomedical Engineer James Collins to Speak for BSA Distinguished Lecture Series April 16th, 2014
ECHA Planning Workshop on Regulatory Challenges in the Risk Assessment of Nanomaterials April 16th, 2014
Lumerical files a provisional patent that extends the standard eigenmode expansion propagation technique to better address waveguide component design. Lumericals EME propagation tool will address a wide set of waveguide applications in silicon photonics and integrated optics April 16th, 2014
UT Arlington physicist creates new nanoparticle for cancer therapy April 16th, 2014
Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply April 15th, 2014
PAM-XIAMEN Offers UV LED wafer April 15th, 2014
Nanocrystalline cellulose modified into an efficient viral inhibitor April 15th, 2014
UT Arlington physicist creates new nanoparticle for cancer therapy April 16th, 2014
Relieving electric vehicle range anxiety with improved batteries: Lithium-sulfur batteries last longer with nanomaterial-packed cathode April 16th, 2014
Aerotech X-Y ball-screw stage for economical high performance Planar positioning April 16th, 2014
Energy Research Facility Construction Project at Brookhaven Lab Wins U.S. Energy Secretary's Achievement Award April 16th, 2014
Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014
Nanoparticles cause cancer cells to self-destruct April 3rd, 2014
A*STAR's Simtech collaboration agreements to accelerate the growth and development of the microfluidics industry April 1st, 2014
Dolomite releases novel droplet-on-demand sequencing and droplet generation microfluidic system April 1st, 2014
Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014
Acid folic was used in the production of the nanogel as targeting agent in drug delivery. The nanogel can be used in the treatment of cancer as a stable nanocarrier. Stability of nanocarriers is an important issue in target delivery mechanisms. Most of nanocarriers, due to their March 17th, 2014
Arrowhead Reports Fiscal 2014 First Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time February 4th, 2014
Arrowhead to Report Fiscal 2014 First Quarter Financial Results - Conference Call Scheduled for Tuesday, February 4, 2014 January 28th, 2014
Targeting cancer with a triple threat: MIT chemists design nanoparticles that can deliver three cancer drugs at a time April 15th, 2014
Biologists Develop Nanosensors to Visualize Movements and Distribution of Plant Stress Hormone April 15th, 2014
In latest generation of tiny biosensors, size isn't everything: UCLA researchers overturn conventional wisdom on nanowire-based diagnostic devices April 11th, 2014
Virus structure inspires novel understanding of onion-like carbon nanoparticles April 10th, 2014